BAXTER BACK-UP PLANS TO NMC ACQUISITION COULD INVOLVE PURCHASE OF SMALLER RENAL SERVICE FIRMS; $3.8 BIL. OFFER FOR NMC WILL NOT BE RAISED, FIRM SAYS
This article was originally published in The Gray Sheet
Baxter's quest to build a vertically integrated dialysis business could put several smaller renal services companies in play as possible acquisition targets if the firm ultimately is unsuccessful in its bid to buy National Medical Care from W.R. Grace. Grace rejected Baxter's $3.8 bil. bid to acquire NMC on Feb. 4 when it announced a definitive agreement with Germany-based Fresenius AG.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.